| Description | This product is a human monoclonal antibody that reacts with IL13RA2. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG1 kappa |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; WB; DB; FuncS |
| Application Notes | The antibody is recommended for detection of IL13RA2 by FuncS assay. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | IL13RA2 |
| Alternative Name | IL13RA2; interleukin 13 receptor, alpha 2; CT19; IL-13R; IL13BP; CD213A2; interleukin-13 receptor subunit alpha-2; IL-13RA2; IL-13R-alpha-2; IL-13R subunit alpha-2; cancer/testis antigen 19; IL-13 receptor subunit alpha-2; interleukin 13 binding protein; interleukin-13-binding protein; interleukin 13 receptor alpha 2 chain |
| Gene ID | 3598 |
| UniProt | Q14627 |
| Research Area | Immunology |
Figure 1 Anti-Human IL13RA2 Monoclonal Antibody (V3S-0622-YC1843) in DB
Dot Blot analysis of V3S-0622-YC1843 was performed by coating with human IL13RA2 protein (His tag).
V3S-0622-YC1843 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 1 Anti-Human IL13RA2 Monoclonal Antibody (V3S-0622-YC1843) in DB
Figure 2 Anti-Human IL13RA2 Monoclonal Antibody (V3S-0622-YC1843) in WB
Western blot analysis of V3S-0622-YC1843 was performed by loading human IL13RA2 protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC1843 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 2 Anti-Human IL13RA2 Monoclonal Antibody (V3S-0622-YC1843) in WB
Figure 3 Anti-Human IL13RA2 Monoclonal Antibody (V3S-0622-YC1843) in ELISA
ELISA analysis of V3S-0622-YC1843 was performed by coating with human IL13RA2 protein (His tag). Then blocked with BSA and incubated with V3S-0622-YC1843. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Anti-Human IL13RA2 Monoclonal Antibody (V3S-0622-YC1843) in ELISA
